L.O.M. is pleased to announce that Dr. Peter Johann has joined the L.O.M. Advisory Board.
Dr. Peter Johann is the Founder, Chairman & CEO of Lumendi Ltd, an innovative Medtech company focusing on devices enabling endoluminal interventions. He is a Managing General Partner of NGN Capital, a healthcare venture capital investor and has had several successful IPOs and M&A transactions in his investment portfolio. He currently serves on the Board of Directors of Noxxon Pharma AG, Vivaldi Biosciences Inc. and Exosome Diagnostics Inc.
Prior to NGN he held several positions in the healthcare industry. He was the Division Head of Corporate Development at Boehringer Ingelheim where he was responsible for strategic planning, strategic projects, M&A, business development and licensing. Prior to this Dr. Johann served at F. Hoffmann-La Roche as Global Business Leader Oncology Products, at Boehringer Mannheim as Head of Business Development and Marketing Molecular Medicine and had Marketing, Sales and Business Development responsibilities at Boehringer Mannheim Biochemicals, among others, for collaborations in the field of Biopharmaceuticals.
L.O.M Believes Dr. Peter Johann should serve on the L.O.M. advisory board based upon his extensive and varied experience in the healthcare industry and business development.